Phase III Study of ISU302 in Patients With Type 1 Gaucher Disease

NCT02770625 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

8

Enrollment

INDUSTRY

Sponsor class

Conditions

Gaucher Disease, Type 1

Interventions

DRUG: ISU302

Sponsor

ISU Abxis Co., Ltd.